Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Under Sanpower, Can Provenge Finally Have A Happy Ending?

Executive Summary

Strategy of focusing immunotherapy on urologists and earlier stage prostate cancer is paying off, says CEO James Caggiano, as Dendreon becomes a standalone company under Chinese conglomerate Sanpower


Related Content

Provenge To Drive Sanpower Growth And Wider China Cell Therapy Market?
Debt-laden Valeant Sells Its Assets, More Divestments Likely
Deal Watch: Valeant’s Financial/Commercial Strength Offers A New Chance For Provenge
Valeant ups bid for Dendreon's Provenge to $400m
Disappointing Provenge Sales Stir Doubts About Demand
Provenge Poised For Broad Insurance Coverage, Despite Grumbles On Price


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts